Swedbank AB Boosts Holdings in Henry Schein, Inc. $HSIC

Swedbank AB raised its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 1.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,312,312 shares of the company’s stock after buying an additional 12,741 shares during the quarter. Swedbank AB owned approximately 1.11% of Henry Schein worth $99,185,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HSIC. AQR Capital Management LLC grew its holdings in Henry Schein by 47.3% in the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after buying an additional 9,756 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Henry Schein by 1.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after buying an additional 229 shares during the period. Acadian Asset Management LLC purchased a new stake in Henry Schein in the 1st quarter valued at about $676,000. Cetera Investment Advisers grew its holdings in Henry Schein by 12.9% in the 2nd quarter. Cetera Investment Advisers now owns 5,561 shares of the company’s stock valued at $406,000 after buying an additional 637 shares during the period. Finally, First Trust Advisors LP grew its holdings in Henry Schein by 0.8% in the 2nd quarter. First Trust Advisors LP now owns 221,130 shares of the company’s stock valued at $16,154,000 after buying an additional 1,669 shares during the period. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Transactions at Henry Schein

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the transaction, the director owned 15,420 shares in the company, valued at $1,217,563.20. This represents a 15.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Philip A. Laskawy sold 2,844 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total value of $228,543.84. Following the completion of the transaction, the director directly owned 21,961 shares in the company, valued at approximately $1,764,785.96. The trade was a 11.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 105,911 shares of company stock worth $8,574,982 over the last 90 days. 0.89% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on HSIC shares. BTIG Research started coverage on Henry Schein in a report on Thursday, April 16th. They set a “neutral” rating for the company. Robert W. Baird set a $97.00 target price on Henry Schein in a report on Wednesday, May 6th. Citigroup started coverage on Henry Schein in a report on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price for the company. Wells Fargo & Company boosted their target price on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Finally, Mizuho decreased their target price on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $86.83.

Henry Schein Stock Up 1.0%

NASDAQ HSIC opened at $74.21 on Friday. The stock has a market cap of $8.45 billion, a PE ratio of 22.42, a P/E/G ratio of 1.86 and a beta of 0.82. Henry Schein, Inc. has a fifty-two week low of $61.94 and a fifty-two week high of $89.29. The business has a 50 day moving average price of $74.34 and a two-hundred day moving average price of $75.62. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The firm had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.Henry Schein’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts predict that Henry Schein, Inc. will post 5.31 EPS for the current fiscal year.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.